Strain Name:

B6.129S2-Irf1tm1Mak/J

Stock Number:

002762

Order this mouse

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use
Type I interferon gene induction is abnormal in homozygous mice. They exhibit impairment of CD8+ T cell and NK cell maturation, impaired IL-12 macrophage production, exclusive Th2 differentiation, and defective Th1.

Description

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating SystemHomozygote x Homozygote         (Female x Male)   01-MAR-06
Specieslaboratory mouse
Background Strain C57BL/6
Donor Strain 129S2 via D3 ES cell line
GenerationN11F39 (27-DEC-13)
Generation Definitions
 
Donating InvestigatorDr. Ronald Schwartz,   National Institutes of Health

Appearance
black
Related Genotype: a/a

Description
Mice homozygous for the Irf1tm1Mak targeted mutation are viable and fertile with no major abnormalities. Type I interferon gene induction is abnormal. These mice exhibit impairment of CD8+ T cell and NK cell maturation, impaired IL-12 macrophage production, exclusive Th2 differentiation, and defective Th1. While these mice are highly susceptible to infections, they have been reported to be resistant to several autoimmune diseases such as collagen-induced arthritis, experimental autoimmune encephalomyelitis, Helicobacter pylori-induced gastritis, induced lymphocytic thyroiditis, insulitis, or diabetes.

Development
A neomycin resistance cassette replaced a 1.2 kb region of the gene, which encodes for amino acids 63 - 223, deleting part of the DNA-binding domain of the protein. The construct was electroporated into D3 ES cells and correctly targeted cells were injected into C57BL/6J blastocysts.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Gastric Cancer   (IRF1)
Lung Cancer   (IRF1)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Irf1tm1Mak/Irf1tm1Mak

        B6.129S2-Irf1tm1Mak/J
  • mortality/aging
  • increased sensitivity to xenobiotic induced morbidity/mortality
    • increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls   (MGI Ref ID J:91927)
    • treatment with recombinant IL12 significantly improves survival of MNU treated mice   (MGI Ref ID J:91927)
  • homeostasis/metabolism phenotype
  • abnormal circulating alanine transaminase level
    • when subjected to warm ischemia/reperfusion (I/R), 60 minutes of warm hepatic ischemia followed by 6 hours of reperfusion significantly increase serum ALT levels in controls, but levels in treated mutants are ~60% lower than I/R-treated wild-type mice   (MGI Ref ID J:111090)
  • increased incidence of tumors by chemical induction
    • following a single dose of MNU most mice develop massive lymphoid neoplasias   (MGI Ref ID J:91927)
    • treatment with recombinant IL12 reduces the incidence of lymphomas in MNU treated mice   (MGI Ref ID J:91927)
  • increased sensitivity to xenobiotic induced morbidity/mortality
    • increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls   (MGI Ref ID J:91927)
    • treatment with recombinant IL12 significantly improves survival of MNU treated mice   (MGI Ref ID J:91927)
  • immune system phenotype
  • abnormal lymphocyte physiology
    • impairment in the ability to produce IFNG in response to Con A stimulation   (MGI Ref ID J:91927)
    • IL12 treatment can rescue the impairment in IFNG production   (MGI Ref ID J:91927)
  • decreased interferon-gamma secretion
    • by lymphocytes following Con A stimulation   (MGI Ref ID J:91927)
    • IL12 treatment can rescue the impairment in IFNG production   (MGI Ref ID J:91927)
  • tumorigenesis
  • increased incidence of tumors by chemical induction
    • following a single dose of MNU most mice develop massive lymphoid neoplasias   (MGI Ref ID J:91927)
    • treatment with recombinant IL12 reduces the incidence of lymphomas in MNU treated mice   (MGI Ref ID J:91927)
  • increased lymphoma incidence
    • following a single dose of MNU compared to similarly treated wild-type controls   (MGI Ref ID J:91927)
  • hematopoietic system phenotype
  • abnormal lymphocyte physiology
    • impairment in the ability to produce IFNG in response to Con A stimulation   (MGI Ref ID J:91927)
    • IL12 treatment can rescue the impairment in IFNG production   (MGI Ref ID J:91927)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Irf1tm1Mak/Irf1+

        either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2)
  • normal phenotype
  • no abnormal phenotype detected
    • mice are viable and fertile, with no detectable abnormalities   (MGI Ref ID J:64286)

Irf1tm1Mak/Irf1tm1Mak

        either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2)
  • hematopoietic system phenotype
  • abnormal T cell number
    • CD8+/CD4+ T cell ratio is lower than wild-type or Irf2-deficient mice during course of LCMV infection   (MGI Ref ID J:64286)
    • decreased CD8-positive, alpha-beta T cell number
      • 10-fold reduction in TCR alpha-beta CD4-CD8+ T cells is observed in peripheral blood, spleen, thymus, and lymph nodes   (MGI Ref ID J:64286)
    • increased CD4-positive, alpha beta T cell number
      • CD4+CD8- T cells are often but not always increased in number in homozygotes   (MGI Ref ID J:64286)
    • increased double-positive T cell number
      • numbers are normal or slightly increased in thymi   (MGI Ref ID J:64286)
  • immune system phenotype
  • *normal* immune system phenotype
    • humoral response to vesicular stomatitis virus challenge is normal; kinetics of immunoglobulin class switching and antibody levels are comparable to wild-type mice   (MGI Ref ID J:64286)
    • abnormal T cell number
      • CD8+/CD4+ T cell ratio is lower than wild-type or Irf2-deficient mice during course of LCMV infection   (MGI Ref ID J:64286)
      • decreased CD8-positive, alpha-beta T cell number
        • 10-fold reduction in TCR alpha-beta CD4-CD8+ T cells is observed in peripheral blood, spleen, thymus, and lymph nodes   (MGI Ref ID J:64286)
      • increased CD4-positive, alpha beta T cell number
        • CD4+CD8- T cells are often but not always increased in number in homozygotes   (MGI Ref ID J:64286)
      • increased double-positive T cell number
        • numbers are normal or slightly increased in thymi   (MGI Ref ID J:64286)
    • abnormal response to infection
      • significantly reduced cytotoxic responses against LCMV-infected target cells are observed   (MGI Ref ID J:64286)

Irf1tm1Mak/Irf1tm1Mak

        involves: 129S2/SvPas
  • cellular phenotype
  • *normal* cellular phenotype
    • apoptosis following UV-induced damage is similar in mutant primary hepatocytes from 6-10 week males and wild-type cells   (MGI Ref ID J:115104)
    • 6-12 hours after UV irradiation, hepatocytes arrest in at G1/S, similar to wild-type cells   (MGI Ref ID J:115104)
    • abnormal DNA repair
      • cultured hepatocytes from 6-10 week males show a defect in DNA repair in an assay in which repair of a UV-damaged reporter plasmid by wild-type and null hepatocytes; recovery of reporter activity by Irf1-deficient hepatocytes is significantly lower than that of wild-type or Trp53-deficient cells   (MGI Ref ID J:115104)
  • homeostasis/metabolism phenotype
  • abnormal DNA repair
    • cultured hepatocytes from 6-10 week males show a defect in DNA repair in an assay in which repair of a UV-damaged reporter plasmid by wild-type and null hepatocytes; recovery of reporter activity by Irf1-deficient hepatocytes is significantly lower than that of wild-type or Trp53-deficient cells   (MGI Ref ID J:115104)

Irf1tm1Mak/Irf1tm1Mak

        involves: 129S2/SvPas * C57BL/6J
  • cardiovascular system phenotype
  • abnormal vascular wound healing
    • 28 days after induction of flow cessation in the common carotid artery, a significant increase of neointima formation was observed proximal of the ligation suture in mutants compared to control wild-type mice   (MGI Ref ID J:118512)
  • homeostasis/metabolism phenotype
  • abnormal vascular wound healing
    • 28 days after induction of flow cessation in the common carotid artery, a significant increase of neointima formation was observed proximal of the ligation suture in mutants compared to control wild-type mice   (MGI Ref ID J:118512)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Irf1tm1Mak related

Immunology, Inflammation and Autoimmunity Research
T Cell Receptor Signaling Defects

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Irf1tm1Mak
Allele Name targeted mutation 1, Tak Mak
Allele Type Targeted (Null/Knockout)
Common Name(s) IRF-1-;
Mutation Made ByDr. Tak Mak,   University Health Network/Un of Toronto
Strain of Origin129S2/SvPas
ES Cell Line NameD3
ES Cell Line Strain129S2/SvPas
Gene Symbol and Name Irf1, interferon regulatory factor 1
Chromosome 11
Gene Common Name(s) AU020929; IRF-1; Irf-1; MAR; expressed sequence AU020929;
Molecular Note A neomycin resistance cassette replaced a 1.2 kb region of the gene, which encodes for amino acids 63 - 223, deleting part of the DNA-binding domain of the protein. [MGI Ref ID J:64286]

Genotyping

Genotyping Information

Genotyping Protocols

Irf1tm1Mak, Melt Curve Analysis
Irf1tm1Mak, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Matsuyama T; Kimura T; Kitagawa M; Pfeffer K; Kawakami T; Watanabe N; Kundig TM; Amakawa R; Kishihara K; Wakeham A; et al. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75(1):83-97. [PubMed: 8402903]  [MGI Ref ID J:64286]

Additional References

Hancock WW; Szaba FM; Berggren KN; Parent MA; Mullarky IK; Pearl J; Cooper AM; Ely KH; Woodland DL; Kim IJ; Blackman MA; Johnson LL; Smiley ST. 2004. Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFN gamma-inducible fibrinogen-like protein 2. Proc Natl Acad Sci U S A 101(9):3005-10. [PubMed: 14976252]  [MGI Ref ID J:88648]

Kimura T; Nakayama K; Penninger J; Kitagawa M; Harada H; Matsuyama T; Tanaka N; Kamijo R; Vilcek J; Mak TW; Taniguchi T. 1994. Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 264(5167):1921-4. [PubMed: 8009222]  [MGI Ref ID J:18880]

Liu J; Cao S; Herman LM; Ma X. 2003. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J Exp Med 198(8):1265-76. [PubMed: 14568984]  [MGI Ref ID J:86244]

Irf1tm1Mak related

Ashkar AA; Black GP; Wei Q; He H; Liang L; Head JR; Croy BA. 2003. Assessment of requirements for IL-15 and IFN regulatory factors in uterine NK cell differentiation and function during pregnancy. J Immunol 171(6):2937-44. [PubMed: 12960317]  [MGI Ref ID J:85375]

Bachmaier K; Neu N; Pummerer C; Duncan GS; Mak TW; Matsuyama T; Penninger JM. 1997. iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. Circulation 96(2):585-91. [PubMed: 9244230]  [MGI Ref ID J:45499]

Berghout J; Langlais D; Radovanovic I; Tam M; MacMicking JD; Stevenson MM; Gros P. 2013. Irf8-regulated genomic responses drive pathological inflammation during cerebral malaria. PLoS Pathog 9(7):e1003491. [PubMed: 23853600]  [MGI Ref ID J:213363]

Biondo C; Malara A; Costa A; Signorino G; Cardile F; Midiri A; Galbo R; Papasergi S; Domina M; Pugliese M; Teti G; Mancuso G; Beninati C. 2012. Recognition of fungal RNA by TLR7 has a nonredundant role in host defense against experimental candidiasis. Eur J Immunol 42(10):2632-43. [PubMed: 22777843]  [MGI Ref ID J:188005]

Biondo C; Signorino G; Costa A; Midiri A; Gerace E; Galbo R; Bellantoni A; Malara A; Beninati C; Teti G; Mancuso G. 2011. Recognition of yeast nucleic acids triggers a host-protective type I interferon response. Eur J Immunol 41(7):1969-79. [PubMed: 21480215]  [MGI Ref ID J:177313]

Blanco JC; Contursi C; Salkowski CA; DeWitt DL; Ozato K; Vogel SN. 2000. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 191(12):2131-44. [PubMed: 10859338]  [MGI Ref ID J:62869]

Bourgeois C; Majer O; Frohner IE; Lesiak-Markowicz I; Hildering KS; Glaser W; Stockinger S; Decker T; Akira S; Muller M; Kuchler K. 2011. Conventional Dendritic Cells Mount a Type I IFN Response against Candida spp. Requiring Novel Phagosomal TLR7-Mediated IFN-{beta} Signaling. J Immunol 186(5):3104-12. [PubMed: 21282509]  [MGI Ref ID J:169378]

Brien JD; Daffis S; Lazear HM; Cho H; Suthar MS; Gale M Jr; Diamond MS. 2011. Interferon regulatory factor-1 (IRF-1) shapes both innate and CD8(+) T cell immune responses against West Nile virus infection. PLoS Pathog 7(9):e1002230. [PubMed: 21909274]  [MGI Ref ID J:183131]

Brummel R; Roberts TL; Stacey KJ; Lenert P. 2006. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice. Eur J Immunol 36(7):1951-62. [PubMed: 16791898]  [MGI Ref ID J:115797]

Burghardt S; Erhardt A; Claass B; Huber S; Adler G; Jacobs T; Chalaris A; Schmidt-Arras D; Rose-John S; Karimi K; Tiegs G. 2013. Hepatocytes contribute to immune regulation in the liver by activation of the Notch signaling pathway in T cells. J Immunol 191(11):5574-82. [PubMed: 24140644]  [MGI Ref ID J:207027]

Cao Z; Dhupar R; Cai C; Li P; Billiar TR; Geller DA. 2010. A Critical Role for IFN Regulatory Factor 1 in NKT Cell-Mediated Liver Injury Induced by {alpha}-Galactosylceramide. J Immunol 185(4):2536-43. [PubMed: 20624945]  [MGI Ref ID J:162383]

Chapman RS; Duff EK; Lourenco PC; Tonner E; Flint DJ; Clarke AR; Watson CJ. 2000. A novel role for IRF-1 as a suppressor of apoptosis. Oncogene 19(54):6386-91. [PubMed: 11175354]  [MGI Ref ID J:123430]

Cho SH; Delehedde M; Rodriguez-Villanueva J; Brisbay S; McDonnell TJ. 2001. Bax gene disruption alters the epidermal response to ultraviolet irradiation and in vivo induced skin carcinogenesis. Int J Mol Med 7(3):235-41. [PubMed: 11179500]  [MGI Ref ID J:67487]

Chou SD; Khan AN; Magner WJ; Tomasi TB. 2005. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol 17(11):1483-94. [PubMed: 16210330]  [MGI Ref ID J:104221]

Clark DA; Chaouat G; Arck PC; Mittruecker HW; Levy GA. 1998. Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothombinase. J Immunol 160(2):545-9. [PubMed: 9551885]  [MGI Ref ID J:45186]

Coers J; Bernstein-Hanley I; Grotsky D; Parvanova I; Howard JC; Taylor GA; Dietrich WF; Starnbach MN. 2008. Chlamydia muridarum evades growth restriction by the IFN-gamma-inducible host resistance factor Irgb10. J Immunol 180(9):6237-45. [PubMed: 18424746]  [MGI Ref ID J:134525]

De Creus A; Van Beneden K; Stevenaert F; Debacker V; Plum J; Leclercq G. 2002. Developmental and functional defects of thymic and epidermal V gamma 3 cells in IL-15-deficient and IFN regulatory factor-1-deficient mice. J Immunol 168(12):6486-93. [PubMed: 12055269]  [MGI Ref ID J:76948]

Dietrich N; Lienenklaus S; Weiss S; Gekara NO. 2010. Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments. PLoS One 5(4):e10250. [PubMed: 20422028]  [MGI Ref ID J:160136]

Dorner M; Horwitz JA; Donovan BM; Labitt RN; Budell WC; Friling T; Vogt A; Catanese MT; Satoh T; Kawai T; Akira S; Law M; Rice CM; Ploss A. 2013. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501(7466):237-41. [PubMed: 23903655]  [MGI Ref ID J:205017]

Eason DD; LeBron C; Coppola D; Moscinski LC; Livingston S; Sutton ET; Blanck G. 2003. Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1. Oncogene 22(40):6166-76. [PubMed: 13679855]  [MGI Ref ID J:85972]

Fantuzzi G; Reed D; Qi M; Scully S; Dinarello CA; Senaldi G. 2001. Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity. Eur J Immunol 31(2):369-75. [PubMed: 11180100]  [MGI Ref ID J:119157]

Feng C; Watanabe S; Maruyama S; Suzuki G; Sato M; Furuta T; Kojima S; Taki S; Asano Y. 1999. An alternate pathway for type 1 T cell differentiation. Int Immunol 11(8):1185-94. [PubMed: 10421776]  [MGI Ref ID J:56761]

Fortier A; Doiron K; Saleh M; Grinstein S; Gros P. 2009. Restriction of Legionella pneumophila replication in macrophages requires concerted action of the transcriptional regulators Irf1 and Irf8 and nod-like receptors Naip5 and Nlrc4. Infect Immun 77(11):4794-805. [PubMed: 19720760]  [MGI Ref ID J:154191]

Fragale A; Gabriele L; Stellacci E; Borghi P; Perrotti E; Ilari R; Lanciotti A; Remoli AL; Venditti M; Belardelli F; Battistini A. 2008. IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell differentiation by repressing Foxp3 expression. J Immunol 181(3):1673-82. [PubMed: 18641303]  [MGI Ref ID J:137875]

Freudenburg W; Gautam M; Chakraborty P; James J; Richards J; Salvatori AS; Baldwin A; Schriewer J; Buller RM; Corbett JA; Skowyra D. 2013. Reduction in ATP levels triggers immunoproteasome activation by the 11S (PA28) regulator during early antiviral response mediated by IFNbeta in mouse pancreatic beta-cells. PLoS One 8(2):e52408. [PubMed: 23383295]  [MGI Ref ID J:199349]

Gabriele L; Fragale A; Borghi P; Sestili P; Stellacci E; Venditti M; Schiavoni G; Sanchez M; Belardelli F; Battistini A. 2006. IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J Leukoc Biol 80(6):1500-11. [PubMed: 16966383]  [MGI Ref ID J:116563]

Geserick P; Kaiser F; Klemm U; Kaufmann SH; Zerrahn J. 2004. Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif. Int Immunol 16(10):1535-48. [PubMed: 15351786]  [MGI Ref ID J:93660]

Gysemans CA; Pavlovic D; Bouillon R; Eizirik DL; Mathieu C. 2001. Dual role of interferon-gamma signalling pathway in sensitivity of pancreatic beta cells to immune destruction. Diabetologia 44(5):567-74. [PubMed: 11380074]  [MGI Ref ID J:107148]

Hancock WW; Szaba FM; Berggren KN; Parent MA; Mullarky IK; Pearl J; Cooper AM; Ely KH; Woodland DL; Kim IJ; Blackman MA; Johnson LL; Smiley ST. 2004. Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFN gamma-inducible fibrinogen-like protein 2. Proc Natl Acad Sci U S A 101(9):3005-10. [PubMed: 14976252]  [MGI Ref ID J:88648]

Hayashi H; Kohno T; Yasui K; Murota H; Kimura T; Duncan GS; Nakashima T; Yamamoto K; Katayama I; Ma Y; Chua KJ; Suematsu T; Shimokawa I; Akira S; Kubo Y; Mak TW; Matsuyama T. 2011. Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2) in trypsinogen5 gene transcription. Proc Natl Acad Sci U S A 108(46):18766-71. [PubMed: 22042864]  [MGI Ref ID J:180225]

Hobart M; Ramassar V; Goes N; Urmson J; Halloran PF. 1997. IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. J Immunol 158(9):4260-9. [PubMed: 9126988]  [MGI Ref ID J:39790]

Honda K; Yanai H; Negishi H; Asagiri M; Sato M; Mizutani T; Shimada N; Ohba Y; Takaoka A; Yoshida N; Taniguchi T. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434(7034):772-7. [PubMed: 15800576]  [MGI Ref ID J:97662]

Iadecola C; Salkowski CA; Zhang F; Aber T; Nagayama M; Vogel SN; Ross ME. 1999. The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J Exp Med 189(4):719-27. [PubMed: 9989987]  [MGI Ref ID J:112019]

Jaruga B; Hong F; Kim WH; Gao B. 2004. IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol 287(5):G1044-52. [PubMed: 15246962]  [MGI Ref ID J:96187]

Jin Z; Mori K; Fujimori K; Hoshikawa S; Tani J; Satoh J; Ito S; Satomi S; Yoshida K. 2004. Experimental autoimmune thyroiditis in nonobese diabetic mice lacking interferon regulatory factor-1. Clin Immunol 113(2):187-92. [PubMed: 15451476]  [MGI Ref ID J:93120]

Kamijo R; Harada H; Matsuyama T; Bosland M; Gerecitano J; Shapiro D; Le J; Koh SI; Kimura T; Green SJ; Mak TW; Taniguchi T; Vilcek J. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263(5153):1612-5. [PubMed: 7510419]  [MGI Ref ID J:17806]

Kano S; Sato K; Morishita Y; Vollstedt S; Kim S; Bishop K; Honda K; Kubo M; Taniguchi T. 2008. The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells. Nat Immunol 9(1):34-41. [PubMed: 18059273]  [MGI Ref ID J:130476]

Karpuzoglu E; Fenaux JB; Phillips RA; Lengi AJ; Elvinger F; Ansar Ahmed S. 2006. Estrogen up-regulates inducible nitric oxide synthase, nitric oxide, and cyclooxygenase-2 in splenocytes activated with T cell stimulants: role of interferon-gamma. Endocrinology 147(2):662-71. [PubMed: 16293660]  [MGI Ref ID J:129444]

Kelchtermans H; Struyf S; De Klerck B; Mitera T; Alen M; Geboes L; Van Balen M; Dillen C; Put W; Gysemans C; Billiau A; Van Damme J; Matthys P. 2007. Protective role of IFN-gamma in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. J Leukoc Biol 81(4):1044-53. [PubMed: 17200147]  [MGI Ref ID J:121452]

Kelley TJ; Elmer HL. 2000. In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J Clin Invest 106(3):403-10. [PubMed: 10930443]  [MGI Ref ID J:111647]

Kim HS; Lee MS. 2005. Essential role of STAT1 in caspase-independent cell death of activated macrophages through the p38 mitogen-activated protein kinase/STAT1/reactive oxygen species pathway. Mol Cell Biol 25(15):6821-33. [PubMed: 16024814]  [MGI Ref ID J:100107]

Kimura T; Kadokawa Y; Harada H; Matsumoto M; Sato M; Kashiwazaki Y; Tarutani M; Tan RS; Takasugi T; Matsuyama T; Mak TW; Noguchi S; Taniguchi T. 1996. Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1(1):115-24. [PubMed: 9078371]  [MGI Ref ID J:77456]

Kimura T; Nakayama K; Penninger J; Kitagawa M; Harada H; Matsuyama T; Tanaka N; Kamijo R; Vilcek J; Mak TW; Taniguchi T. 1994. Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 264(5167):1921-4. [PubMed: 8009222]  [MGI Ref ID J:18880]

Ko J; Gendron-Fitzpatrick A; Splitter GA. 2002. Susceptibility of IFN regulatory factor-1 and IFN consensus sequence binding protein-deficient mice to brucellosis. J Immunol 168(5):2433-40. [PubMed: 11859135]  [MGI Ref ID J:74725]

Lee HJ; Oh YK; Rhee M; Lim JY; Hwang JY; Park YS; Kwon Y; Choi KH; Jo I; Park SI; Gao B; Kim WH. 2007. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN. J Mol Biol 369(4):967-84. [PubMed: 17475277]  [MGI Ref ID J:122801]

Liu J; Guan X; Ma X. 2005. Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon {gamma}-induced RANTES/CCl5 expression in macrophages. J Biol Chem 280(26):24347-55. [PubMed: 15860458]  [MGI Ref ID J:133228]

Liu J; Guan X; Ma X. 2007. Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. J Exp Med 204(1):141-52. [PubMed: 17227910]  [MGI Ref ID J:125292]

Liu J; Xiang Z; Ma X. 2004. Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma. J Immunol 173(2):1184-93. [PubMed: 15240709]  [MGI Ref ID J:91927]

Lohoff M; Duncan GS; Ferrick D; Mittrucker HW; Bischof S; Prechtl S; Rollinghoff M; Schmitt E; Pahl A; Mak TW. 2000. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J Exp Med 192(3):325-36. [PubMed: 10934221]  [MGI Ref ID J:63876]

Mannick EE; Cote RL; Schurr JR; Krowicka HS; Sloop GD; Zapata-Velandia A; Correa H; Ruiz B; Horswell R; Lentz JJ; Byrne P; Gastanaduy MM; Hornick CA; Liu Z. 2005. Altered phenotype of dextran sulfate sodium colitis in interferon regulatory factor-1 knock-out mice. J Gastroenterol Hepatol 20(3):371-80. [PubMed: 15740479]  [MGI Ref ID J:97866]

McWhirter SM; Barbalat R; Monroe KM; Fontana MF; Hyodo M; Joncker NT; Ishii KJ; Akira S; Colonna M; Chen ZJ; Fitzgerald KA; Hayakawa Y; Vance RE. 2009. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med 206(9):1899-911. [PubMed: 19652017]  [MGI Ref ID J:152182]

Molle C; Goldman M; Goriely S. 2010. Critical role of the IFN-stimulated gene factor 3 complex in TLR-mediated IL-27p28 gene expression revealing a two-step activation process. J Immunol 184(4):1784-92. [PubMed: 20083668]  [MGI Ref ID J:159478]

Nakazawa T; Satoh J; Takahashi K; Sakata Y; Ikehata F; Takizawa Y; Bando SI; Housai T; Li Y; Chen C; Masuda T; Kure S; Kato I; Takasawa S; Taniguchi T; Okamoto H; Toyota T. 2001. Complete Suppression of Insulitis and Diabetes in NOD mice Lacking Interferon Regulatory Factor-1. J Autoimmun 17(2):119-25. [PubMed: 11591120]  [MGI Ref ID J:71799]

Nozawa H; Oda E; Nakao K; Ishihara M; Ueda S; Yokochi T; Ogasawara K; Nakatsuru Y; Shimizu S; Ohira Y; Hioki K; Aizawa S; Ishikawa T; Katsuki M; Muto T; Taniguchi T; Tanaka N. 1999. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 13(10):1240-5. [PubMed: 10346812]  [MGI Ref ID J:55418]

Ohteki T; Maki C; Koyasu S. 2001. Overexpression of Bcl-2 differentially restores development of thymus-derived CD4-8+ T cells and intestinal intraepithelial T cells in IFN-regulatory factor-1-deficient mice. J Immunol 166(11):6509-13. [PubMed: 11359801]  [MGI Ref ID J:69487]

Oliveira-dos-Santos AJ; Penninger JM; Rieker-Geley T; Matsumoto G; Mak TM; Wick G. 1998. Thymic heterotypic cellular complexes in gene-targeted mice with defined blocks in T cell development and adhesion molecule expression. Eur J Immunol 28(9):2882-92. [PubMed: 9754575]  [MGI Ref ID J:49877]

Parker D; Prince A. 2012. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J Immunol 189(8):4040-6. [PubMed: 22962685]  [MGI Ref ID J:190532]

Pavlovic D; Chen MC; Gysemans CA; Mathieu C; Eizirik DL. 1999. The role of interferon regulatory factor-1 in cytokine-induced mRNA expression and cell death in murine pancreatic beta-cells. Eur Cytokine Netw 10(3):403-11. [PubMed: 10477397]  [MGI Ref ID J:59499]

Penninger JM; Sirard C; Mittrucker HW; Chidgey A; Kozieradzki I; Nghiem M; Hakem A; Kimura T; Timms E; Boyd R; Taniguchi T; Matsuyama T; Mak TW. 1997. The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes. Immunity 7(2):243-54. [PubMed: 9285409]  [MGI Ref ID J:111439]

Prost S; Bellamy CO; Cunningham DS; Harrison DJ. 1998. Altered DNA repair and dysregulation of p53 in IRF-1 null hepatocytes. FASEB J 12(2):181-8. [PubMed: 9472983]  [MGI Ref ID J:115104]

Reilly CM; Olgun S; Goodwin D; Gogal RM Jr; Santo A; Romesburg JW; Ahmed SA; Gilkeson GS. 2006. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol 36(5):1296-308. [PubMed: 16541466]  [MGI Ref ID J:114771]

Rosborough BR; Raich-Regue D; Matta BM; Lee K; Gan B; DePinho RA; Hackstein H; Boothby M; Turnquist HR; Thomson AW. 2013. Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood 121(18):3619-30. [PubMed: 23444404]  [MGI Ref ID J:197572]

Salkowski CA; Barber SA; Detore GR; Vogel SN. 1996. Differential dysregulation of nitric oxide production in macrophages with targeted disruptions in IFN regulatory factor-1 and -2 genes. J Immunol 156(9):3107-10. [PubMed: 8617930]  [MGI Ref ID J:110841]

Salkowski CA; Kopydlowski K; Blanco J; Cody MJ; McNally R; Vogel SN. 1999. IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice. J Immunol 163(3):1529-36. [PubMed: 10415056]  [MGI Ref ID J:56995]

Salkowski CA; Thomas KE; Cody MJ; Vogel SN. 2000. Impaired IFN-gamma production in IFN regulatory factor-1 knockout mice during endotoxemia is secondary to a loss of both IL-12 and IL-12 receptor expression J Immunol 165(7):3970-7. [PubMed: 11034406]  [MGI Ref ID J:64864]

Schmitz F; Heit A; Guggemoos S; Krug A; Mages J; Schiemann M; Adler H; Drexler I; Haas T; Lang R; Wagner H. 2007. Interferon-regulatory-factor 1 controls Toll-like receptor 9-mediated IFN-beta production in myeloid dendritic cells. Eur J Immunol 37(2):315-27. [PubMed: 17273999]  [MGI Ref ID J:117901]

Senaldi G; Shaklee CL; Guo J; Martin L; Boone T; W Mak T; Ulich TR. 1999. Protection against the mortality associated with disease models mediated by TNF and IFN-gamma in mice lacking IFN regulatory factor-1. J Immunol 163(12):6820-6. [PubMed: 10586082]  [MGI Ref ID J:58986]

Sharma S; Deoliveira RB; Kalantari P; Parroche P; Goutagny N; Jiang Z; Chan J; Bartholomeu DC; Lauw F; Hall JP; Barber GN; Gazzinelli RT; Fitzgerald KA; Golenbock DT. 2011. Innate Immune Recognition of an AT-Rich Stem-Loop DNA Motif in the Plasmodium falciparum Genome. Immunity 35(2):194-207. [PubMed: 21820332]  [MGI Ref ID J:175845]

Siegmund B; Sennello JA; Lehr HA; Senaldi G; Dinarello CA; Fantuzzi G. 2004. Frontline: Interferon regulatory factor-1 as a protective gene in intestinal inflammation: role of TCR gamma delta T cells and interleukin-18-binding protein. Eur J Immunol 34(9):2356-64. [PubMed: 15307168]  [MGI Ref ID J:91767]

Sjostrand M; Ambrosi A; Brauner S; Sullivan J; Malin S; Kuchroo VK; Espinosa A; Wahren-Herlenius M. 2013. Expression of the immune regulator tripartite-motif 21 is controlled by IFN regulatory factors. J Immunol 191(7):3753-63. [PubMed: 23975864]  [MGI Ref ID J:205843]

Skyberg JA; Thornburg T; Kochetkova I; Layton W; Callis G; Rollins MF; Riccardi C; Becker T; Golden S; Pascual DW. 2012. IFN-gamma-deficient mice develop IL-1-dependent cutaneous and musculoskeletal inflammation during experimental brucellosis. J Leukoc Biol 92(2):375-87. [PubMed: 22636321]  [MGI Ref ID J:186167]

Taki S; Sato T; Ogasawara K; Fukuda T; Sato M; Hida S; Suzuki G; Mitsuyama M; Shin EH; Kojima S; Taniguchi T; Asano Y. 1997. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6(6):673-9. [PubMed: 9208840]  [MGI Ref ID J:111528]

Tan RS; Feng C; Asano Y; Kara AU. 1999. Altered immune response of interferon regulatory factor 1-deficient mice against Plasmodium berghei blood-stage malaria infection. Infect Immun 67(5):2277-83. [PubMed: 10225884]  [MGI Ref ID J:55978]

Testa U; Stellacci E; Pelosi E; Sestili P; Venditti M; Orsatti R; Fragale A; Petrucci E; Pasquini L; Belardelli F; Gabriele L; Battistini A. 2004. Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. Leukemia 18(11):1864-71. [PubMed: 15385939]  [MGI Ref ID J:94400]

Tsung A; Stang MT; Ikeda A; Critchlow ND; Izuishi K; Nakao A; Chan MH; Jeyabalan G; Yim JH; Geller DA. 2006. The transcription factor interferon regulatory factor-1 mediates liver damage during ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 290(6):G1261-8. [PubMed: 16410367]  [MGI Ref ID J:111090]

Venkatesh D; Ernandez T; Rosetti F; Batal I; Cullere X; Luscinskas FW; Zhang Y; Stavrakis G; Garcia-Cardena G; Horwitz BH; Mayadas TN. 2013. Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-beta autocrine signaling to promote monocyte recruitment. Immunity 38(5):1025-37. [PubMed: 23623383]  [MGI Ref ID J:203156]

Wang Y; John R; Chen J; Richardson JA; Shelton JM; Bennett M; Zhou XJ; Nagami GT; Zhang Y; Wu QQ; Lu CY. 2009. IRF-1 promotes inflammation early after ischemic acute kidney injury. J Am Soc Nephrol 20(7):1544-55. [PubMed: 19443641]  [MGI Ref ID J:164963]

Weiss G; Maaetoft-Udsen K; Stifter SA; Hertzog P; Goriely S; Thomsen AR; Paludan SR; Frokiaer H. 2012. MyD88 drives the IFN-beta response to Lactobacillus acidophilus in dendritic cells through a mechanism involving IRF1, IRF3, and IRF7. J Immunol 189(6):2860-8. [PubMed: 22896628]  [MGI Ref ID J:189947]

Wessely R; Hengst L; Jaschke B; Wegener F; Richter T; Lupetti R; Paschalidis M; Schomig A; Brandl R; Neumann FJ. 2003. A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia. Hum Mol Genet 12(2):177-87. [PubMed: 12499398]  [MGI Ref ID J:118512]

Yang H; Lee SM; Gao B; Zhang J; Fang D. 2013. Histone deacetylase sirtuin 1 deacetylates IRF1 protein and programs dendritic cells to control Th17 protein differentiation during autoimmune inflammation. J Biol Chem 288(52):37256-66. [PubMed: 24214980]  [MGI Ref ID J:207189]

Yu Q; Vazquez R; Khojeini EV; Patel C; Venkataramani R; Larson DF. 2009. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol 297(1):H76-85. [PubMed: 19429811]  [MGI Ref ID J:151107]

Zhang J; Qian X; Ning H; Yang J; Xiong H; Liu J. 2010. Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J Biol Chem 285(28):21269-81. [PubMed: 20435892]  [MGI Ref ID J:165363]

Zoller EE; Lykens JE; Terrell CE; Aliberti J; Filipovich AH; Henson PM; Jordan MB. 2011. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 208(6):1203-14. [PubMed: 21624938]  [MGI Ref ID J:176823]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX11

Colony Maintenance

Breeding & HusbandryWhen maintaining the live colony, homozygous mice may be bred together. The expected coat color from breeding is Black.
Mating SystemHomozygote x Homozygote         (Female x Male)   01-MAR-06
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $199.90Female or MaleHomozygous for Irf1tm1Mak  
Price per Pair (US dollars $)Pair Genotype
$399.80Homozygous for Irf1tm1Mak x Homozygous for Irf1tm1Mak  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $259.90Female or MaleHomozygous for Irf1tm1Mak  
Price per Pair (US dollars $)Pair Genotype
$519.80Homozygous for Irf1tm1Mak x Homozygous for Irf1tm1Mak  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)